Although KRAS mutation does not represent the typical genetic state of SRCC, it suggests that mFOLFOX6 plus cetuximab therapy might promote other oncogene mutations or epigenetic changes, causing the transformation of non-SRCC CRC to SRCC. This evidence concerns the gene KRAS and colorectal carcinoma.